Osteonecrosis of the Jaw in a Patient on Denosumab

Overview

Journal J Oral Maxillofac Surg

Specialties Dentistry
General Surgery

Date 2010 Feb 13

PMID 20149510

Citations 85

Authors

Tara L Aghaloo

Alan L Felsenfeld

Sotirios Tetradis

Affiliations

Soon will be listed here.

Citing Articles

The role of leukocyte and platelet-rich fibrin in the prevention of medication-related osteonecrosis of the jaw, in patients requiring dental extractions: an observational study.

Besi E, Pitros P Oral Maxillofac Surg. 2024; 28(2):785-793.

PMID: 38182917 DOI: 10.1007/s10006-023-01204-z.

Laputkova G, Talian I, Schwartzova V Int J Mol Sci. 2023; 24(23).

PMID: 38069068 PMC: 10706386. DOI: 10.3390/ijms242316745.

Management of a rare mandibular giant cell tumor of bone by neoadjuvant denosumab therapy and surgery: A 4-year follow-up case report.

Klienkoff P, Weingertner N, Geyer L, Gros C, Kurtz J, Bornert F Int J Surg Case Rep. 2023; 112:108980.

PMID: 37913666 PMC: 10667875. DOI: 10.1016/j.ijscr.2023.108980.

Anti-resorptive therapy in the osteometabolic patient affected by periodontitis. A joint position paper of the Italian Society of Orthopaedics and Traumatology (SIOT) and the Italian Society of Periodontology and Implantology (SIdP).

Landi L, Leali P, Barbato L, Carrassi A, Discepoli N, Muti P J Orthop Traumatol. 2023; 24(1):36.

PMID: 37453950 PMC: 10349795. DOI: 10.1186/s10195-023-00713-7.

Denosumab-associated jaw bone necrosis in cancer patients: retrospective descriptive case series study.

Kang J, Kim S, Lim J, Kim J, Jin G, Lee Y Maxillofac Plast Reconstr Surg. 2023; 45(1):23.

PMID: 37389685 PMC: 10313599. DOI: 10.1186/s40902-023-00391-9.

References

Shipman C, Rogers M, Apperley J, Russell R, Croucher P . Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol. 1997; 98(3):665-72. DOI: 10.1046/j.1365-2141.1997.2713086.x. View

Reid I, Bolland M, Grey A . Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?. Bone. 2007; 41(3):318-20. DOI: 10.1016/j.bone.2007.04.196. View

Pozzi S, Marcheselli R, Sacchi S, Baldini L, Angrilli F, Pennese E . Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. Leuk Lymphoma. 2007; 48(1):56-64. DOI: 10.1080/10428190600977690. View

Lipton A, Steger G, Figueroa J, Alvarado C, Solal-Celigny P, Body J . Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol. 2007; 25(28):4431-7. DOI: 10.1200/JCO.2007.11.8604. View

Morgan T, Atkins G, Trivett M, Johnson S, Kansara M, Schlicht S . Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol. 2005; 167(1):117-28. PMC: 1603441. DOI: 10.1016/s0002-9440(10)62959-8. View

Coxon F, Helfrich M, vant Hof R, Sebti S, Ralston S, Hamilton A . Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res. 2000; 15(8):1467-76. DOI: 10.1359/jbmr.2000.15.8.1467. View

Ruggiero S, Fantasia J, Carlson E . Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006; 102(4):433-41. DOI: 10.1016/j.tripleo.2006.06.004. View

Farah C, Savage N . Oral ulceration with bone sequestration. Aust Dent J. 2003; 48(1):61-4. DOI: 10.1111/j.1834-7819.2003.tb00011.x. View

Ruggiero S, Dodson T, Assael L, Landesberg R, Marx R, Mehrotra B . American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg. 2009; 67(5 Suppl):2-12. DOI: 10.1016/j.joms.2009.01.009. View

10.

Boyle W, Simonet W, Lacey D . Osteoclast differentiation and activation. Nature. 2003; 423(6937):337-42. DOI: 10.1038/nature01658. View

11.

Bekker P, Holloway D, Rasmussen A, Murphy R, Martin S, Leese P . A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2004; 19(7):1059-66. DOI: 10.1359/JBMR.040305. View

12.

Glueck C, McMahon R, Bouquot J, Tracy T, Wang P . A preliminary pilot study of treatment of thrombophilia and hypofibrinolysis and amelioration of the pain of osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998; 85(1):64-73. DOI: 10.1016/s1079-2104(98)90400-0. View

13.

Ruggiero S, Mehrotra B, Rosenberg T, Engroff S . Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004; 62(5):527-34. DOI: 10.1016/j.joms.2004.02.004. View

14.

Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson D . Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 1991; 88(6):2095-105. PMC: 295810. DOI: 10.1172/JCI115539. View

15.

Schwartz H . Osteonecrosis of the jaws: a complication of cancer chemotherapy. Head Neck Surg. 1982; 4(3):251-3. DOI: 10.1002/hed.2890040313. View

16.

Migliorati C . Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol. 2003; 21(22):4253-4. DOI: 10.1200/JCO.2003.99.132. View

17.

Marx R, Cillo Jr J, Ulloa J . Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007; 65(12):2397-410. DOI: 10.1016/j.joms.2007.08.003. View

18.

Shane E, Goldring S, Christakos S, Drezner M, Eisman J, Silverman S . Osteonecrosis of the jaw: more research needed. J Bone Miner Res. 2006; 21(10):1503-5. DOI: 10.1359/jbmr.060712. View

19.

Tarassoff P, Csermak K . Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg. 2003; 61(10):1238-9. DOI: 10.1016/j.joms.2003.09.001. View

20.

Brown J, Prince R, Deal C, Recker R, Kiel D, de Gregorio L . Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2008; 24(1):153-61. DOI: 10.1359/jbmr.0809010. View